Global (United States, European Union and China) Impetigo Drug

Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Players and Region - Global Market Outlook to 2030

Impetigo Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Type
  • FMX-102
  • LTX-109
  • Mupirocin
  • Ozenoxacin
  • Others
By Route of Administration
  • Topical
  • Oral

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of the Disease
      • 3.2.2. Increasing Awareness and Low Cost Of Treatment
      • 3.2.3. The Rising Population of Minors and Infants
    • 3.3. Market Challenges
      • 3.3.1. Limited Options of Advanced Medication and Therapeutics
    • 3.4. Market Trends
      • 3.4.1. The Introduction of Improved Versions of Mupirocin, Synthetic Peptides and Ozenoxacin at a Reasonable Price Range
      • 3.4.2. The Growing Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Impetigo Drug, by Type, Route of Administration, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Impetigo Drug (Value)
      • 5.2.1. Global Impetigo Drug by: Type (Value)
        • 5.2.1.1. FMX-102
        • 5.2.1.2. LTX-109
        • 5.2.1.3. Mupirocin
        • 5.2.1.4. Ozenoxacin
        • 5.2.1.5. Others
      • 5.2.2. Global Impetigo Drug by: Route of Administration (Value)
        • 5.2.2.1. Topical
        • 5.2.2.2. Oral
      • 5.2.3. Global Impetigo Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Pharmacy
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Impetigo Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Impetigo Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Destiny Pharma Ltd. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Foamix Pharmaceuticals Ltd. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Orchid Chemicals & Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Laboratories Ojer Pharma SL (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lytix Biopharma AS (Norway)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cutanea Life Sciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NovaBay Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Impetigo Drug Sale, by Type, Route of Administration, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Impetigo Drug (Value)
      • 7.2.1. Global Impetigo Drug by: Type (Value)
        • 7.2.1.1. FMX-102
        • 7.2.1.2. LTX-109
        • 7.2.1.3. Mupirocin
        • 7.2.1.4. Ozenoxacin
        • 7.2.1.5. Others
      • 7.2.2. Global Impetigo Drug by: Route of Administration (Value)
        • 7.2.2.1. Topical
        • 7.2.2.2. Oral
      • 7.2.3. Global Impetigo Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Pharmacy
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Impetigo Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Impetigo Drug: by Type(USD Million)
  • Table 2. Impetigo Drug FMX-102 , by Region USD Million (2018-2023)
  • Table 3. Impetigo Drug LTX-109 , by Region USD Million (2018-2023)
  • Table 4. Impetigo Drug Mupirocin , by Region USD Million (2018-2023)
  • Table 5. Impetigo Drug Ozenoxacin , by Region USD Million (2018-2023)
  • Table 6. Impetigo Drug Others , by Region USD Million (2018-2023)
  • Table 7. Impetigo Drug: by Route of Administration(USD Million)
  • Table 8. Impetigo Drug Topical , by Region USD Million (2018-2023)
  • Table 9. Impetigo Drug Oral , by Region USD Million (2018-2023)
  • Table 10. Impetigo Drug: by Distribution Channel(USD Million)
  • Table 11. Impetigo Drug Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Impetigo Drug Online Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Impetigo Drug Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 14. South America Impetigo Drug, by Country USD Million (2018-2023)
  • Table 15. South America Impetigo Drug, by Type USD Million (2018-2023)
  • Table 16. South America Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 17. South America Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 18. Brazil Impetigo Drug, by Type USD Million (2018-2023)
  • Table 19. Brazil Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 20. Brazil Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 21. Argentina Impetigo Drug, by Type USD Million (2018-2023)
  • Table 22. Argentina Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 23. Argentina Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 24. Rest of South America Impetigo Drug, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 26. Rest of South America Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 27. Asia Pacific Impetigo Drug, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Impetigo Drug, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 30. Asia Pacific Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 31. China Impetigo Drug, by Type USD Million (2018-2023)
  • Table 32. China Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 33. China Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 34. Japan Impetigo Drug, by Type USD Million (2018-2023)
  • Table 35. Japan Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 36. Japan Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 37. India Impetigo Drug, by Type USD Million (2018-2023)
  • Table 38. India Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 39. India Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 40. South Korea Impetigo Drug, by Type USD Million (2018-2023)
  • Table 41. South Korea Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 42. South Korea Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 43. Taiwan Impetigo Drug, by Type USD Million (2018-2023)
  • Table 44. Taiwan Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 45. Taiwan Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 46. Australia Impetigo Drug, by Type USD Million (2018-2023)
  • Table 47. Australia Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 48. Australia Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Impetigo Drug, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 52. Europe Impetigo Drug, by Country USD Million (2018-2023)
  • Table 53. Europe Impetigo Drug, by Type USD Million (2018-2023)
  • Table 54. Europe Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 55. Europe Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 56. Germany Impetigo Drug, by Type USD Million (2018-2023)
  • Table 57. Germany Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 58. Germany Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 59. France Impetigo Drug, by Type USD Million (2018-2023)
  • Table 60. France Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 61. France Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 62. Italy Impetigo Drug, by Type USD Million (2018-2023)
  • Table 63. Italy Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 64. Italy Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 65. United Kingdom Impetigo Drug, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 67. United Kingdom Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 68. Netherlands Impetigo Drug, by Type USD Million (2018-2023)
  • Table 69. Netherlands Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 70. Netherlands Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Europe Impetigo Drug, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 73. Rest of Europe Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 74. MEA Impetigo Drug, by Country USD Million (2018-2023)
  • Table 75. MEA Impetigo Drug, by Type USD Million (2018-2023)
  • Table 76. MEA Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 77. MEA Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 78. Middle East Impetigo Drug, by Type USD Million (2018-2023)
  • Table 79. Middle East Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 80. Middle East Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 81. Africa Impetigo Drug, by Type USD Million (2018-2023)
  • Table 82. Africa Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 83. Africa Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 84. North America Impetigo Drug, by Country USD Million (2018-2023)
  • Table 85. North America Impetigo Drug, by Type USD Million (2018-2023)
  • Table 86. North America Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 87. North America Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 88. United States Impetigo Drug, by Type USD Million (2018-2023)
  • Table 89. United States Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 90. United States Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 91. Canada Impetigo Drug, by Type USD Million (2018-2023)
  • Table 92. Canada Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 93. Canada Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 94. Mexico Impetigo Drug, by Type USD Million (2018-2023)
  • Table 95. Mexico Impetigo Drug, by Route of Administration USD Million (2018-2023)
  • Table 96. Mexico Impetigo Drug, by Distribution Channel USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Impetigo Drug: by Type(USD Million)
  • Table 107. Impetigo Drug FMX-102 , by Region USD Million (2025-2030)
  • Table 108. Impetigo Drug LTX-109 , by Region USD Million (2025-2030)
  • Table 109. Impetigo Drug Mupirocin , by Region USD Million (2025-2030)
  • Table 110. Impetigo Drug Ozenoxacin , by Region USD Million (2025-2030)
  • Table 111. Impetigo Drug Others , by Region USD Million (2025-2030)
  • Table 112. Impetigo Drug: by Route of Administration(USD Million)
  • Table 113. Impetigo Drug Topical , by Region USD Million (2025-2030)
  • Table 114. Impetigo Drug Oral , by Region USD Million (2025-2030)
  • Table 115. Impetigo Drug: by Distribution Channel(USD Million)
  • Table 116. Impetigo Drug Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 117. Impetigo Drug Online Pharmacy , by Region USD Million (2025-2030)
  • Table 118. Impetigo Drug Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 119. South America Impetigo Drug, by Country USD Million (2025-2030)
  • Table 120. South America Impetigo Drug, by Type USD Million (2025-2030)
  • Table 121. South America Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 122. South America Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 123. Brazil Impetigo Drug, by Type USD Million (2025-2030)
  • Table 124. Brazil Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 125. Brazil Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 126. Argentina Impetigo Drug, by Type USD Million (2025-2030)
  • Table 127. Argentina Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 128. Argentina Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 129. Rest of South America Impetigo Drug, by Type USD Million (2025-2030)
  • Table 130. Rest of South America Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 131. Rest of South America Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 132. Asia Pacific Impetigo Drug, by Country USD Million (2025-2030)
  • Table 133. Asia Pacific Impetigo Drug, by Type USD Million (2025-2030)
  • Table 134. Asia Pacific Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 135. Asia Pacific Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 136. China Impetigo Drug, by Type USD Million (2025-2030)
  • Table 137. China Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 138. China Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 139. Japan Impetigo Drug, by Type USD Million (2025-2030)
  • Table 140. Japan Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 141. Japan Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 142. India Impetigo Drug, by Type USD Million (2025-2030)
  • Table 143. India Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 144. India Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 145. South Korea Impetigo Drug, by Type USD Million (2025-2030)
  • Table 146. South Korea Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 147. South Korea Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 148. Taiwan Impetigo Drug, by Type USD Million (2025-2030)
  • Table 149. Taiwan Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 150. Taiwan Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 151. Australia Impetigo Drug, by Type USD Million (2025-2030)
  • Table 152. Australia Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 153. Australia Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Impetigo Drug, by Type USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 157. Europe Impetigo Drug, by Country USD Million (2025-2030)
  • Table 158. Europe Impetigo Drug, by Type USD Million (2025-2030)
  • Table 159. Europe Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 160. Europe Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 161. Germany Impetigo Drug, by Type USD Million (2025-2030)
  • Table 162. Germany Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 163. Germany Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 164. France Impetigo Drug, by Type USD Million (2025-2030)
  • Table 165. France Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 166. France Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 167. Italy Impetigo Drug, by Type USD Million (2025-2030)
  • Table 168. Italy Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 169. Italy Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 170. United Kingdom Impetigo Drug, by Type USD Million (2025-2030)
  • Table 171. United Kingdom Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 172. United Kingdom Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 173. Netherlands Impetigo Drug, by Type USD Million (2025-2030)
  • Table 174. Netherlands Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 175. Netherlands Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 176. Rest of Europe Impetigo Drug, by Type USD Million (2025-2030)
  • Table 177. Rest of Europe Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 178. Rest of Europe Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 179. MEA Impetigo Drug, by Country USD Million (2025-2030)
  • Table 180. MEA Impetigo Drug, by Type USD Million (2025-2030)
  • Table 181. MEA Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 182. MEA Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 183. Middle East Impetigo Drug, by Type USD Million (2025-2030)
  • Table 184. Middle East Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 185. Middle East Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 186. Africa Impetigo Drug, by Type USD Million (2025-2030)
  • Table 187. Africa Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 188. Africa Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 189. North America Impetigo Drug, by Country USD Million (2025-2030)
  • Table 190. North America Impetigo Drug, by Type USD Million (2025-2030)
  • Table 191. North America Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 192. North America Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 193. United States Impetigo Drug, by Type USD Million (2025-2030)
  • Table 194. United States Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 195. United States Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 196. Canada Impetigo Drug, by Type USD Million (2025-2030)
  • Table 197. Canada Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 198. Canada Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 199. Mexico Impetigo Drug, by Type USD Million (2025-2030)
  • Table 200. Mexico Impetigo Drug, by Route of Administration USD Million (2025-2030)
  • Table 201. Mexico Impetigo Drug, by Distribution Channel USD Million (2025-2030)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Impetigo Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Impetigo Drug: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Impetigo Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Impetigo Drug Share (%), by Country
  • Figure 8. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 9. Europe Impetigo Drug Share (%), by Country
  • Figure 10. MEA Impetigo Drug Share (%), by Country
  • Figure 11. North America Impetigo Drug Share (%), by Country
  • Figure 12. Global Impetigo Drug share by Players 2023 (%)
  • Figure 13. Global Impetigo Drug share by Players (Top 3) 2023(%)
  • Figure 14. Global Impetigo Drug share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Destiny Pharma Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Destiny Pharma Ltd. (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Foamix Pharmaceuticals Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Foamix Pharmaceuticals Ltd. (United States) Revenue: by Geography 2023
  • Figure 20. Orchid Chemicals & Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 21. Orchid Chemicals & Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 22. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 24. Laboratories Ojer Pharma SL (Spain) Revenue, Net Income and Gross profit
  • Figure 25. Laboratories Ojer Pharma SL (Spain) Revenue: by Geography 2023
  • Figure 26. Lytix Biopharma AS (Norway) Revenue, Net Income and Gross profit
  • Figure 27. Lytix Biopharma AS (Norway) Revenue: by Geography 2023
  • Figure 28. Cutanea Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 29. Cutanea Life Sciences (United States) Revenue: by Geography 2023
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 32. NovaBay Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. NovaBay Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 34. Global Impetigo Drug: by Type USD Million (2025-2030)
  • Figure 35. Global Impetigo Drug: by Route of Administration USD Million (2025-2030)
  • Figure 36. Global Impetigo Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 37. South America Impetigo Drug Share (%), by Country
  • Figure 38. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 39. Europe Impetigo Drug Share (%), by Country
  • Figure 40. MEA Impetigo Drug Share (%), by Country
  • Figure 41. North America Impetigo Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Destiny Pharma Ltd. (United Kingdom)
  • Foamix Pharmaceuticals Ltd. (United States)
  • Orchid Chemicals & Pharmaceuticals (India)
  • Roche Holding AG (Switzerland)
  • Laboratories Ojer Pharma SL (Spain)
  • Lytix Biopharma AS (Norway)
  • Cutanea Life Sciences (United States)
  • GlaxoSmithKline (United Kingdom)
  • NovaBay Pharmaceuticals (United States)
Additional players considered in the study are as follows:
LEO Pharma (Denmark) , Medimetriks Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 241 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Impetigo Drug Quantitative research analysis
Global (United States, European Union and China) Impetigo Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global (United States, European Union and China) Impetigo Drug Report?

Have a Query? Click Here

Other Related Reports

Clomifene Citrate Comprehensive Study by Application (Hospital, Clinics, Fertility Center), Form (Tablet, Injection), Distribution Channel (Hospital Pharmacies, Medical Stores, Online Pharmacies), En...
$ 3800
Frankincense Oil Comprehensive Study by Type (Natural Frankincense Oil, Synthetic Frankincense Oil), Application (Medicine, Skin care, Oral Care , Others), Distribution Channel (Direct, Indirect (Spe...
$ 3500
Pycnogenol Comprehensive Study by Application (Nutraceutical, Personal and Skin Care Products, Food and Beverages, Health Supplements, Others), Distribution Channel (Direct Sale (Online, Offline), Di...
$ 3450
Protein Kinase Inhibitor Comprehensive Study by Type (Serine/Threonine Protein Kinase Inhibitors, Tyrosine Protein Kinase Inhibitor), Application (Lung Cancer, Breast Cancer, Renal Cell Cancer, Other...
$ 3750
Raloxifene Hydrochloride Comprehensive Study by Type (Tablet, Capsule), Application (Pharmaceuticals, Chemicals, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Online Channels...
$ 3800
Pharmaceutical Boric Acid Comprehensive Study by Application (Antifungal, Antibacterial), End-users (Hospitals, Clinics, Others), Form (Powder, Liquid), Distribution Channel (Online Channel, Offline ...
$ 3500